Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 1/2009

01.01.2009 | Original Paper

Preoperative hemoglobin and platelet count and poor prognostic factors in patients with endometrial carcinoma

verfasst von: Jale Metindir, Gülay Bilir Dilek

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 1/2009

Einloggen, um Zugang zu erhalten

Abstract

Objective

The aim of this study was to evaluate the relationship between preoperative hemoglobin and platelet count and prognostic factors in patients with endometrial cancer.

Methods

Sixty-one patients with endometrial carcinoma who underwent surgical treatment consisting of total abdominal hysterectomy, bilateral salpingo-oophorectomy, infracolic omentectomy, pelvic and para-aortic lymph node dissection, and peritoneal cytology were retrospectively analyzed. Preoperative hemoglobin and platelet count, pelvic and para-aortic lymph node status, depth of myometrial invasion, grade, lymphovascular invasion (LVSI), adnexal involvement, positive peritoneal cytology, cervical stromal invasion, and tumor size were investigated. Kruskal–Wallis, Mann–Whitney U, Fishers Exact and Chi-square tests were used for univariate analyses. The multivariate analysis was performed with logistic regression analyses.

Results

Twenty-six (42.6%) patients had a pre-treatment hemoglobin value of ≤12 g/dL. These 26 patients had significantly higher rates of positive cytology (P = 0.008), advanced FIGO stage (P = 0.03), omental metastases (P = 0.01), cervical involvement (P = 0.02), and thrombocytosis (P = 0.02). The multivariate analysis revealed cervical involvement (P = 0.019, OR = 4.030, 95% CI = 1.255–12.947) and positive peritoneal cytology (P = 0.022, OR = 12.509, 95% CI = 1.43–109.36) to be significantly associated with low hemoglobin level. In the univariate analysis, the presence of cervical involvement and lymphatic metastasis were associated with significantly higher median preoperative platelet counts.

Conclusion

Low pre-treatment hemoglobin level may reflect poor prognostic factors such as positive cytology and cervical involvement in patients with endometrial cancer that is associated with thrombocytosis.
Literatur
Zurück zum Zitat Ayhan A, Bozdağ G, Taşkıran Ç, Gültekin M, Yüce K, Küçükali T (2006) The value of preoperative platelet count in the prediction of cervical involvement and poor prognostic variables in patients with endometrial carcinoma. Gynecol Oncol 103:902–905. doi:10.1016/j.ygyno.2006.05.034 PubMedCrossRef Ayhan A, Bozdağ G, Taşkıran Ç, Gültekin M, Yüce K, Küçükali T (2006) The value of preoperative platelet count in the prediction of cervical involvement and poor prognostic variables in patients with endometrial carcinoma. Gynecol Oncol 103:902–905. doi:10.​1016/​j.​ygyno.​2006.​05.​034 PubMedCrossRef
Zurück zum Zitat Berridge MV, Fraser JK, Carter JM, Li FK (1988) Effects of recombinant erytropoietin on megakaryocytes and on platelet production in the rat. Blood 72:970–977PubMed Berridge MV, Fraser JK, Carter JM, Li FK (1988) Effects of recombinant erytropoietin on megakaryocytes and on platelet production in the rat. Blood 72:970–977PubMed
Zurück zum Zitat Bozkurt N, Yüce K, Başaran M, Köse F, Ayhan A (2004) Correlation of platelet count with second-look laparotomy results and disease progression in patients with advanced epithelial ovarian cancer. Obstet Gynecol 103:82–85PubMed Bozkurt N, Yüce K, Başaran M, Köse F, Ayhan A (2004) Correlation of platelet count with second-look laparotomy results and disease progression in patients with advanced epithelial ovarian cancer. Obstet Gynecol 103:82–85PubMed
Zurück zum Zitat Chopra V, Dinh TV, Hannigan EV (1997) Serum levels of interleukins, growth factors and angiogenin in patients with endometrial carcinoma. J Cancer Res Clin Oncol 123:167–172PubMed Chopra V, Dinh TV, Hannigan EV (1997) Serum levels of interleukins, growth factors and angiogenin in patients with endometrial carcinoma. J Cancer Res Clin Oncol 123:167–172PubMed
Zurück zum Zitat Hernandez E, Lavine M, Dunton CJ, Gracely E, Parker J (1992) Poor prognosis associated with thrombocytosis in patients with epithelial cervical cancer. Cancer 69:2975–2977. doi:10.1002/1097-0142(19920615)69:12<2975::AID-CNCR2820691218>3.0.CO;2-APubMedCrossRef Hernandez E, Lavine M, Dunton CJ, Gracely E, Parker J (1992) Poor prognosis associated with thrombocytosis in patients with epithelial cervical cancer. Cancer 69:2975–2977. doi:10.1002/1097-0142(19920615)69:12<2975::AID-CNCR2820691218>3.0.CO;2-APubMedCrossRef
Zurück zum Zitat Hernandez E, Donohue KA, Anderson LL, Heller PB, Stehman FB (2000) The significance of thrombocytosis in patients with locally advanced cervical carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 78:137–142. doi:10.1006/gyno.2000.5838 PubMedCrossRef Hernandez E, Donohue KA, Anderson LL, Heller PB, Stehman FB (2000) The significance of thrombocytosis in patients with locally advanced cervical carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 78:137–142. doi:10.​1006/​gyno.​2000.​5838 PubMedCrossRef
Zurück zum Zitat Logsdon MD, Eifel PJ (1999) FIGO stage IIIB squamous cell carcinoma of the cervix: an analysis of prognostic factors emphasizing the balance between external beam and intracavitary radiation therapy. Int J Radiat Oncol Biol Phys 43:763–775. doi:10.1016/S0360-3016(98)00482-9 PubMed Logsdon MD, Eifel PJ (1999) FIGO stage IIIB squamous cell carcinoma of the cervix: an analysis of prognostic factors emphasizing the balance between external beam and intracavitary radiation therapy. Int J Radiat Oncol Biol Phys 43:763–775. doi:10.​1016/​S0360-3016(98)00482-9 PubMed
Zurück zum Zitat Lopes A, Daras V, Cross PA, Robertson G, Beynon G, Monaghan JM (1994) Thrombocytosis as a prognostic factor in women with cervical cancer. Cancer 74:90–92. doi:10.1002/1097-0142(19940701)74:1<90::AID-CNCR2820740116>3.0.CO;2-0PubMedCrossRef Lopes A, Daras V, Cross PA, Robertson G, Beynon G, Monaghan JM (1994) Thrombocytosis as a prognostic factor in women with cervical cancer. Cancer 74:90–92. doi:10.1002/1097-0142(19940701)74:1<90::AID-CNCR2820740116>3.0.CO;2-0PubMedCrossRef
Zurück zum Zitat Menczer J, Geva D, Schejter E, Zakut H (1996) Elevated platelet count in patients with endometrial carcinoma: correlation with selected prognostic factors and with survival. Int J Gynecol Cancer 6:463–466CrossRef Menczer J, Geva D, Schejter E, Zakut H (1996) Elevated platelet count in patients with endometrial carcinoma: correlation with selected prognostic factors and with survival. Int J Gynecol Cancer 6:463–466CrossRef
Zurück zum Zitat Mundt AJ, Connell PP, Campbell T, Hwang JH, Rotmensch J, Waggoner S (1998) Race and clinical outcome in patients with carcinoma of the uterine cervix treated with radiation therapy. Gynecol Oncol 71:1511–1515. doi:10.1006/gyno.1998.5203 CrossRef Mundt AJ, Connell PP, Campbell T, Hwang JH, Rotmensch J, Waggoner S (1998) Race and clinical outcome in patients with carcinoma of the uterine cervix treated with radiation therapy. Gynecol Oncol 71:1511–1515. doi:10.​1006/​gyno.​1998.​5203 CrossRef
Zurück zum Zitat Obermair A, Handisurya A, Kaider A, Sevelda P, Kölbl H, Gitsch G (1998) The relationship of pretreatment serum hemoglobin level to the survival of epithelial ovarian carcinoma patients. Cancer 83:726–731. doi: 10.1002/(SICI)1097-0142(19980815)83:4<726::AID-CNCR14>3.0.CO;2-UPubMedCrossRef Obermair A, Handisurya A, Kaider A, Sevelda P, Kölbl H, Gitsch G (1998) The relationship of pretreatment serum hemoglobin level to the survival of epithelial ovarian carcinoma patients. Cancer 83:726–731. doi: 10.1002/(SICI)1097-0142(19980815)83:4<726::AID-CNCR14>3.0.CO;2-UPubMedCrossRef
Zurück zum Zitat Salgado R, Vermeulen PB, Benoy I, Weytjens R, Huget P, Van Marck E et al (1999) Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. Br J Cancer 80:892–897. doi:10.1038/sj.bjc.6690437 PubMedCrossRef Salgado R, Vermeulen PB, Benoy I, Weytjens R, Huget P, Van Marck E et al (1999) Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. Br J Cancer 80:892–897. doi:10.​1038/​sj.​bjc.​6690437 PubMedCrossRef
Zurück zum Zitat Scholtz HS, Petru E, Gucer F, Haas J, Tamussino K, Winter R (2000) Preoperative thrombocytosis is an independent prognostic factor in stage III and IV endometrial cancer. Anticancer Res 20:3983–3985 Scholtz HS, Petru E, Gucer F, Haas J, Tamussino K, Winter R (2000) Preoperative thrombocytosis is an independent prognostic factor in stage III and IV endometrial cancer. Anticancer Res 20:3983–3985
Zurück zum Zitat Silverberg SG, Kurman RJ, Nogales F (2003) Tumours of the uterine corpus. In: Tavassoli FA, Devilee P (eds) World Health Organization classification of tumors. Pathology and genetics of tumours of the breast and female genital organs. IARC press, Lyon, pp 221–232 Silverberg SG, Kurman RJ, Nogales F (2003) Tumours of the uterine corpus. In: Tavassoli FA, Devilee P (eds) World Health Organization classification of tumors. Pathology and genetics of tumours of the breast and female genital organs. IARC press, Lyon, pp 221–232
Zurück zum Zitat Spivak JL (1994) Cancer-related anemia: its causes and characteristics. Semin Oncol 21(Suppl):3–8PubMed Spivak JL (1994) Cancer-related anemia: its causes and characteristics. Semin Oncol 21(Suppl):3–8PubMed
Zurück zum Zitat Tranum BL, Haut A (1974) Thrombocytosis: platelet kinetics in neoplasia. J Lab Clin Med 84:615–619PubMed Tranum BL, Haut A (1974) Thrombocytosis: platelet kinetics in neoplasia. J Lab Clin Med 84:615–619PubMed
Zurück zum Zitat van der Zee AG, de Cuyper EM, Limburg PC, de Bruijn HW, Hollema H, Bijzet J et al (1995) Higher levels of interleukin-6 in cystic fluids from patients with malignant versus benign ovarian tumors correlate with decreased hemoglobin levels and increased platelet counts. Cancer 75:1004–1009. doi: 10.1002/1097-0142(19950215)75:4<1004::AID-CNCR2820750416>3.0.CO;2-GPubMedCrossRef van der Zee AG, de Cuyper EM, Limburg PC, de Bruijn HW, Hollema H, Bijzet J et al (1995) Higher levels of interleukin-6 in cystic fluids from patients with malignant versus benign ovarian tumors correlate with decreased hemoglobin levels and increased platelet counts. Cancer 75:1004–1009. doi: 10.1002/1097-0142(19950215)75:4<1004::AID-CNCR2820750416>3.0.CO;2-GPubMedCrossRef
Zurück zum Zitat Zeimet AG, Marth C, Muller-Holzner E, Daxenbichler G, Dapunt O (1994) Significance of thrombocytosis in patients with epithelial ovarian cancer. Am J Obstet Gynecol 170:549–554PubMed Zeimet AG, Marth C, Muller-Holzner E, Daxenbichler G, Dapunt O (1994) Significance of thrombocytosis in patients with epithelial ovarian cancer. Am J Obstet Gynecol 170:549–554PubMed
Metadaten
Titel
Preoperative hemoglobin and platelet count and poor prognostic factors in patients with endometrial carcinoma
verfasst von
Jale Metindir
Gülay Bilir Dilek
Publikationsdatum
01.01.2009
Verlag
Springer-Verlag
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 1/2009
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-008-0430-2

Weitere Artikel der Ausgabe 1/2009

Journal of Cancer Research and Clinical Oncology 1/2009 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.